🇺🇸 Alendronate (Fosamax) in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 13

Most-reported reactions

1. Chronic Obstructive Pulmonary Disease — 2 reports (15.38%)
2. Fatigue — 2 reports (15.38%)
3. Sepsis — 2 reports (15.38%)
4. Acute Myocardial Infarction — 1 report (7.69%)
5. Band Neutrophil Count Increased — 1 report (7.69%)
6. Bone Disorder — 1 report (7.69%)
7. Brain Natriuretic Peptide Increased — 1 report (7.69%)
8. Bronchiectasis — 1 report (7.69%)
9. Cerebrovascular Accident — 1 report (7.69%)
10. Confusional State — 1 report (7.69%)

Source database →

Frequently asked questions

Is Alendronate (Fosamax) approved in United States?

Alendronate (Fosamax) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Alendronate (Fosamax) in United States?

Medical University of South Carolina is the originator. The local marketing authorisation holder may differ — check the official source linked above.